Reimbursement Review Reports


( Last Updated : May 25, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Botox OnabotulinumtoxinA Migraine Do not list Complete
Botox OnabotulinumtoxinA Urinary incontinence List with criteria/condition Complete
Braftovi encorafenib Metastatic colorectal cancer Reimburse with clinical criteria and/or conditions Complete
Braftovi and Mektovi encorafenib and binimetinib Advanced Melanoma Reimburse with clinical criteria and/or conditions Complete
Brenzys Etanercept Rheumatoid arthritis, Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Breo Ellipta Fluticasone furoate /vilanterol Chronic Obstructive Pulmonary Disease (COPD) List with criteria/condition Complete
Breo Ellipta Fluticasone Furoate and Vilanterol (as trifenatate) Asthma List with clinical criteria and/or conditions Complete
Breo Ellipta fluticasone furoate/vilanterol Asthma Withdrawn
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn
Breztri Aerosphere budesonide/ glycopyrronium /formoterol fumarate chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete